Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
MWN-AI** Summary
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has announced the promotion of Mas Matsuda, JD, to the role of Executive Vice President and Chief Legal Officer as part of the company’s strategic growth phase. Matsuda, who has served as Senior Vice President and General Counsel since joining Arcutis in January 2022, will retain responsibility for leading the company's legal, compliance, and governance strategies. This alignment is crucial as Arcutis continues to commercialize its innovative ZORYVE® (roflumilast) product portfolio and safeguard its intellectual property.
Frank Watanabe, President and CEO of Arcutis expressed his enthusiasm for Matsuda's promotion, highlighting his pivotal role in enhancing the company's legal foundation and supporting the successful growth trajectory of ZORYVE. As Arcutis prepares for what it describes as an "exciting next phase of growth," Matsuda's expertise and steady leadership are anticipated to be vital in expanding its commercial presence and advancing its therapeutic pipeline.
Matsuda brings extensive experience to his new position, having previously held key legal roles, including Senior Vice President and General Counsel at Halozyme Therapeutics, Inc., and various legal positions at Amgen. His contributions to Arcutis include guiding the company through significant commercial developments, including six FDA approvals for ZORYVE.
In his statement, Matsuda expressed pride in Arcutis' progress in medical dermatology and looks forward to aiding the company in addressing the needs of individuals suffering from immune-mediated skin diseases. This promotion comes at a pivotal time as Arcutis aims to bolster its market presence and achieve sustained success in dermatological innovations.
MWN-AI** Analysis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has recently announced the promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer, a strategic move intended to fortify the company's growth phase. Given Matsuda's extensive experience in the biopharmaceutical sector, combined with his successful track record at Arcutis, this appointment signals a commitment to strengthening legal and compliance frameworks as the company commercializes its ZORYVE® (roflumilast) portfolio.
Investors should view this leadership transition as a positive indicator of Arcutis' growth strategy, particularly as the company expands its presence within the immuno-dermatology space. The ZORYVE portfolio has already achieved substantial milestones, including multiple FDA approvals for its innovative topical treatments for various dermatological conditions. As Arcutis continues to navigate regulatory landscapes and corporate transactions, particularly under Matsuda's legal guidance, stability and strategic growth should follow.
Furthermore, the ongoing development of a robust pipeline is essential for long-term success. Arcutis’ focus on meaningful innovations in treating immune-mediated skin diseases positions the company favorably within the biopharmaceutical landscape. Investors should keep a close watch on upcoming clinical trials and any announcements regarding new product indications, as these can significantly influence market sentiment and stock performance.
However, it is crucial to remain cognizant of potential risks, such as competition from emerging therapies, reimbursement challenges, and market penetration hurdles. As noted in recent filings, understanding the full risk landscape is key to evaluating Arcutis' future success.
In conclusion, the promotion of Mas Matsuda reflects Arcutis' strategic intent to build upon its success, and his leadership in legal and compliance will be fundamental as the company pursues its next phase of growth. Investors may consider this a time to assess their positions in ARQT, as ongoing advancements may yield opportunities for substantial returns in the evolving dermatological market.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the promotion of Mas Matsuda, JD, currently senior vice president and general counsel, to executive vice president, chief legal officer, and corporate secretary. Mr. Matsuda will continue to lead the Company’s legal, compliance, and governance strategy in support of the continued growth of the Company, commercialization of the ZORYVE® (roflumilast) portfolio, and protection of the Company’s intellectual property, as well as any corporate transactions.
“I am thrilled to announce Mas’ promotion,” said Frank Watanabe, president and chief executive officer of Arcutis. “Since joining Arcutis, Mas has been a trusted adviser and an instrumental leader, strengthening our legal and compliance foundation while supporting the successful development and growth of ZORYVE. As we highlighted in our recent fourth quarter and full-year results, Arcutis is entering an exciting next phase of growth. Mas’ strategic judgment, deep expertise, and steady leadership will be critical as we continue to expand our commercial presence and advance our portfolio.”
Mr. Matsuda joined Arcutis in January 2022 as general counsel and corporate secretary, leading legal and compliance strategy and serving as secretary to the Board of Directors. He has helped guide the Company through a period of significant commercial growth, including six FDA approvals of the Company’s advanced targeted topical, ZORYVE, while building and scaling the Company’s legal, compliance, and governance framework. Prior to Arcutis, Mr. Matsuda served as senior vice president, general counsel, chief compliance officer, and corporate secretary at Halozyme Therapeutics, Inc. and previously held numerous legal positions including vice president, law, global commercial operations at Amgen.
“Over the past four years, Arcutis has evolved into a leader in medical dermatology with a successful ZORYVE franchise and an advancing pipeline,” said Mas Matsuda, JD. “I am proud to continue contributing to the Company’s momentum and look forward to working alongside our leadership team as we enter the next phase of growth, delivering meaningful innovation for individuals suffering from immune-mediated skin diseases and positioning the Company for sustained, long-term success.”
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform, coupled with our dermatology expertise allows us to develop differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.
INDICATIONS
ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age.
ZORYVE cream, 0.15%, is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older.
ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older.
ZORYVE topical foam, 0.3%, is indicated for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older.
ZORYVE topical foam, 0.3%, is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.
IMPORTANT SAFETY INFORMATION
ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).
Flammability: The propellants in ZORYVE foam are flammable. Avoid fire, flame, and smoking during and immediately following application.
The most common adverse reactions reported (?1%) for ZORYVE cream 0.05% for pediatric patients with atopic dermatitis 2 to 5 years of age were upper respiratory tract infection (4.1%), diarrhea (2.5%), vomiting (2.1%), rhinitis (1.6%), conjunctivitis (1.4%), and headache (1.1%).
The most common adverse reactions reported (?1%) for ZORYVE cream 0.15% for patients with atopic dermatitis 6 years of age or older were headache (2.9%), nausea (1.9%), application site pain (1.5%), diarrhea (1.5%), and vomiting (1.5%).
The most common adverse reactions reported (?1%) for ZORYVE cream 0.3% for plaque psoriasis were diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary tract infection (1.0%).
The most common adverse reactions reported (?1%) for ZORYVE foam 0.3% for plaque psoriasis were headache (3.1%), diarrhea (2.5%), nausea (1.7%), and nasopharyngitis (1.3%).
The most common adverse reactions reported (?1%) for ZORYVE foam 0.3% for seborrheic dermatitis were nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).
Please see full Prescribing Information for ZORYVE cream and full Prescribing Information for ZORYVE foam.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the Company’s potential growth and pipeline advancement. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2026, as well as any subsequent filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Brian Schoelkopf, Head of Investor Relations
ir@arcutis.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bfa6aea2-02c7-4796-b448-9743b310ac22
FAQ**
How does Arcutis Biotherapeutics Inc. (ARQT) plan to enhance its intellectual property protections under the leadership of Mas Matsuda, now the chief legal officer?
What future corporate transactions does Arcutis Biotherapeutics Inc. (ARQT) foresee that could impact its growth trajectory, especially regarding the ZORYVE portfolio?
With six FDA approvals for ZORYVE, how does Arcutis Biotherapeutics Inc. (ARQT) envision expanding its commercialization efforts in the next few years?
How does Mas Matsuda's experience from Halozyme Therapeutics and Amgen strengthen Arcutis Biotherapeutics Inc. (ARQT) during this next phase of growth and innovation in immuno-dermatology?
**MWN-AI FAQ is based on asking OpenAI questions about Arcutis Biotherapeutics Inc. (NASDAQ: ARQT).
NASDAQ: ARQT
ARQT Trading
3.8% G/L:
$24.475 Last:
346,296 Volume:
$23.92 Open:
